System and method for treating meibomian gland dysfunction
View Patent ↗Systems and methods of treating meibomian and sebaceous gland dysfunction. The methods include reducing oxygen concentration in the environment of one or more dysfunctional meibomian and sebaceous glands, thereby restoring a hypoxic status of one or more dysfunctional meibomian and sebaceous glands. The reducing of the oxygen concentration is accomplished by restricting blood flow to the one or more dysfunctional meibomian and sebaceous glands and the environment of one or more dysfunctional meibomian sebaceous glands. The restricting of the blood flow is accomplished by contracting or closing one or more blood vessels around the one or more dysfunctional meibomian or sebaceous glands. The methods also include giving local or systemic drugs that lead to the generation of hypoxia-inducible factors in one or more dysfunctional meibomian and sebaceous glands.
1. A method of treating meibomian gland dysfunction, the method comprising:
identifying loss of hypoxic status in an eyelid environment of a patient; and
reducing oxygen concentration or inducing hypoxia-inducible factors in said eyelid environment of one or more dysfunctional meibomian glands, thereby restoring a hypoxic status of the eyelid environment or stimulating hypoxia-related pathways in the one or more dysfunctional meibomian glands,
wherein the reducing of the oxygen concentration is accomplished by restricting blood flow to the one or more dysfunctional meibomian glands and the eyelid environment of one or more dysfunctional meibomian glands, and
wherein restricting the blood flow consists essentially of application of a 532-nm potassium titanyl phosphate (KTP) laser, a 532-nm neodymium yttrium-aluminum-garnet (Nd:YAG) laser, a 578-nm copper vapor laser, 585-600-nm pulsed dye laser (PDL), a dual 595-nm PDL, a long-pulse alexandrite (755 nm), a 800-983-nm diode laser, a 1,064-nm Nd:YAG laser, or indocyanine green augmented laser therapy.
2. The method of claim 1 , wherein the restricting of the blood flow is accomplished by contracting or closing one or more blood vessels around the one or more dysfunctional meibomian glands.
3. The method of claim 1 , wherein the hypoxic status is induced pharmaceutically.
4. The method of claim 1 , wherein the hypoxic status is induced surgically.
5. A method of treating meibomian gland dysfunction, the method comprising:
identifying loss of hypoxic status in an eyelid environment of a patient; and
reducing oxygen concentration or inducing hypoxia-inducible factors in aft said eyelid environment of one or more dysfunctional meibomian glands, thereby restoring a hypoxic status of the eyelid environment or stimulating hypoxia-related pathways in the one or more dysfunctional meibomian glands,
wherein the reducing of the oxygen concentration is accomplished by restricting blood flow to the one or more dysfunctional meibomian glands and the eyelid environment of one or more dysfunctional meibomian glands,
wherein restricting the blood flow is achieved using one or more of a 532-nm potassium titanyl phosphate (KTP) laser, a 532-nm neodymium yttrium-aluminum-garnet (Nd:YAG) laser, a 578-nm copper vapor laser, 585-600-nm pulsed dye laser (PDL), a dual 595-nm PDL, a long-pulse alexandrite (755 nm), a 800-983-nm diode laser, a 1,064-nm Nd:YAG laser, indocyanine green augmented laser therapy, PDL treatment combined with rapamycin, intense pulsed light (IPL), carbon dioxide (CO2) laser, cryotherapy, vascular endothelial growth factor (VEGF)/vascular endothelial growth factor receptor (VEGFR) inhibitors or antagonists, systemic and/or local beta-blockers, anti-angiogenic molecules and mixtures thereof, and
wherein the hypoxic status is induced using an intense-pulsed light.
6. The method of claim 1 , wherein the hypoxic status is induced with a device.
7. The method of claim 1 , wherein the hypoxic status is induced using hypoxia chamber goggles.
8. The method of claim 3 , wherein the hypoxic status is induced by prolyl hydroxylases inhibitors, Dimethyloxalylglycine (DMOG), desferrioxamine (DFX) or cobalt chloride (CoCl2).
9. The method of claim 8 , wherein the prolyl hydroxylases inhibitors comprise one or more of FG-4592/roxadustat, FG-2216, daprodustat/GSK1278863, vadadustat/AKB-6548, molidustat/BAY 85-3934, and desidustat/ZYAN1.
10. The method of claim 1 , wherein telangiectasia of said eyelid is identified in said patient.